Olivia Vizier

Last month, Jessie Jackson’s friends and family sang her happy birthday a little early. Jessie doesn’t turn 30 until Dec. 12, but for the past five years on the anniversary of her diagnosis, her parents have hosted a fundraiser. They weren’t taking any chances.

Pfizer must have liked what it saw in data presented by Cardiff Oncology for a challenger in KRAS-mutated cancers. The Big Pharma is putting up a $15 million equity investment in the biotech to help bankroll development of the drug. 

“Fountain is an example of a biotech company emerging as a direct result of basic research, in this case the biology of aging,” said Dr Rando, founder and chairman of Fountain. “The company’s screening and discovery platform is built upon foundational research showing that the age of a cell can be modulated by factors in

When you’re heading up a fledgling biotech out to make a name for yourself in the middle of a wild industry boom, there’s one sure way to differentiate yourself that’s bound to attract universal nods.

While anti-depressants and therapy have helped, Evanston-based biotech company Aptinyx have a pill in the pipeline that they hope will prevent the trauma that triggers PTSD.

Meet the second group of 14 executives being honored in 2021.

Orchestra BioMed presentedlong-term clinical results and ISH subgroup data from the MODERATO II trial of BackBeat Cardiac Neuromodulation Therapy in patients with hypertension and an indication for a pacemaker. The results demonstrated a mean reduction of 17.5 mmHg in office systolic blood pressure in all BackBeat CNT treated patients who completed 24-month follow-up.

In late 2017, Discovery Labs was at the brink of falling apart. The company’s investors pulled out after Aerosurf, its sole remaining asset being developed as a treatment for premature infants with respiratory distress syndrome, failed to meet its endpoints in a Phase IIb study.

One of the greatest recent innovations in cancer treatment, CAR T therapies have sent some patients into long-lasting remission, with speedier recoveries, due to the lack of aggressive chemotherapy involved. They are the darling of numerous biopharma companies, including Sorrento Therapeutics, Kite Pharma (Gilead), and Allogene Therapeutics.

Pharmacokinetics data on vurolenatide, a long-acting glucagon-like peptide-1 (GLP-1) being developed for short-bowel syndrome (SBS), suggest that the drug could be given twice monthly or less, an improvement over existing GLP-2 drugs, which must be given at least weekly.

Dutch biotech firm ProQR Therapeutics announced it had struck its own RNA-editing partnership with Eli Lilly and Company to develop therapies for liver and nervous system diseases.

On October 21st, Sio Gene Therapies Inc. made two major announcements featuring one of its lead gene therapy candidates. The New York-based company presented positive interim data for AXO-AAV-GM1, its AAV9-based gene therapy for GM1 gangliosidosis, at the ESGCT Virtual Congress 2021. On the same day, it also announced the FDA’s Fast Track Designation granted

Cerevance at Cambridge Science Park is on the cusp of discovering potential treatment options. Since inception, the company has collected more than 250 billion transcripts of data as part of research into degenerative brain diseases.

Sio Gene Therapies had already reported decent results with a low dose of AXO-AAV-GM1, its gene therapy candidate for the rare inherited disease GM1 gangliosidosis. Now it has posted even more impressive data with a high dose of the project.

In fact, “approximately 95% of gene therapies today use adeno-associated viruses (AAVs) to deliver a transgene to its target. However, because the AAVs are highly immunogenic, you can’t give a second dose,” Carsten Brunn, Ph.D., president and CEO of Selecta Biosciences, told BioSpace. To further compound matters, Brunn added, “up to 40% of patients have antibodies

In an interview with PharmaShots, Paula Ragan, Ph.D., President, and Chief Executive Officer at X4 Pharmaceuticals shared her views on preliminary efficacy and safety data of Mavorixafor + Ibrutinib in an ongoing P-Ib study to treat waldenström’s macroglobulinemia

Aligos’ CHB portfolio includes STOPS (S-antigen transport-inhibiting oligonucleotide polymers), CAM (capsid assembly modulator), ASO (antisense oligonucleotide) and siRNA (small interfering RNA) candidates.

American depositary receipts of Valneva jumped more than 30% Monday after the French biotech said that phase-3 trials of its Covid-19 vaccine VLA2001 had shown it triggered a stronger immune response and fewer side-effects than the shot of competitor AstraZeneca.

Among them is MeiraGTx Holdings, shares of which fell from a 2019 peak of $30 to a recent $14, leaving its market capitalization below $600 million—and only a half-dozen analysts paying it heed.

People with celiac most likely experience diarrhea due to intestinal inflammation and damage caused by gluten, says Patrick Griffin, MD, gastroenterology specialist and Chief Medical Officer of 9 Meters Biopharma.

When startup TFF Pharmaceuticals raised $14 million in a series A in 2018, its intention was to deploy its dry-powder drug-delivery technology toward making novel inhalable therapies for asthma, chronic obstructive pulmonary disease and other serious lung diseases. Then COVID-19 hit, and the company saw an opportunity to apply the platform to the emerging virus.

Don’t call Noubar Afeyan a venture capitalist. Sure, the 59-year-old founder and CEO of “venture creation” firm Flagship Pioneering has helped launch some 70 biotech companies in the past several decades. But Flagship both backs and performs the original scientific research of his portfolio companies. Its best-known launch is Moderna (ticker: MRNA), the vaccine-developer and

Selecta’s platform makes use of a biodegradable nanoparticle that encapsulates the immunosuppressive drug rapamycin, and is designed to be given in conjunction with gene therapies to induce antigen-specific immune tolerance.

Brad Margus, chief executive of drug-discovery company Cerevance, said that lowering drug prices will especially hurt companies working on the hardest-to-crack diseases, where even though a drug that works would have a huge market, it’s nearly impossible to persuade investors to support new approaches. “The price controls now being pushed threaten to remove the chance for

Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies. “Approved cell therapy products have a very, very high response rate,” he said. “The challenge is in expanding that therapy from hematologic malignancies to other targets – in particular, to solid tumors – where we, as a field, haven’t yet cracked the

Dale Christensen is the Director of Clinical Development at TFF Pharmaceuticals. It’s an Austin-based company and specializes in “Thin Film Freezing”—a technology first created at UT Austin.

Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.